CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Citius Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Citius Pharmaceuticals Inc
11 Commerce Dr Fl 1
Phone: (908) 967-6677p:908 967-6677 CRANFORD, NJ  07016-3501  United States Ticker: CTXRCTXR
Business Summary
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20249/30/2024YesYes-YesYes

Industries
SIC Code Description
3714 Motor vehicle parts and accessories
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer, Company Secretary Leonard L.Mazur 78 5/1/2022 9/1/2014
Executive Vice Chairman of the Board Myron Z.Holubiak 76 5/1/2022 10/6/2015
Chief Financial Officer, Chief Business Officer JaimeBartushak 56 5/1/2022 11/27/2017
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Citius Oncology Inc 420 Lexington Ave,, Suite 2446 NEW YORK NY United States

Business Names
Business Name
Citius Acquisition Corp.
Citius Oncology, Inc.
Citius Pharmaceuticals, LLC
5 additional Business Names available in full report.

General Information
Number of Employees: 23 (As of 9/30/2024)
Outstanding Shares: 8,593,433 (As of 1/14/2025)
Shareholders: 91
Stock Exchange: NASD
Federal Tax Id: 273425913


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025